N/A N=18 Single-blind Other

Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

Chronic Sinusitis

Bottom Line

View on ClinicalTrials.gov: NCT00626366 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2019

Primary outcome: Primary: To Measure the Distribution of Nasal Sprays and Drops. — 18; 17; 16; 17 nasal cavities (right and left sides)

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Sinus CT Scan (Radiation); Omnipaque 240 Contrast Solution (Drug); Omnipaque 240 mg I/mL (Drug)
Age: Adult, Older Adult · 19+ yrs
Sex: All
Sponsor: University of Nebraska
Primary completion: Jan 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY To Measure the Distribution of Nasal Sprays and Drops.	18; 17; 16; 17; 0; 6	—

Summary

The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used.

Eligibility Criteria

Inclusion Criteria

adult able to perform activities of daily living

Exclusion Criteria

signs or symptoms of acute or chronic paranasal sinus disease
history of sinus surgery
symptomatic deviated septum
active seasonal allergies
allergies to contrast
history of nasal polyposis
pregnant or breast feeding women
neck or back problems that would prevent a subject from kneeling on the floor and crouching over
currently taking metformin or amiodarone
students or stff under the direct supervision of the investigators
cognitive impairment
terminal illness

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00626366). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.